Human pluripotent stem cell-derived secretome as a biologic for prevention and treatment of neurodegenerative and apoptotic diseases

A method of protecting mammalian cells from oxidative stress, and/or mitochondrial dysfunction, and/or inflammatory gene expression, and/or protein aggregation, and/or toxin induced cell death, said method comprising:

• contacting said cells with an effective amount of one or more of the following:
• a) unfractionated iPS cell derived secretome, where said iPS cells are derived from a mammal with a neurodegenerative pathology or a healthy mammal;
• b) heparin bound and/or unbound fractions of iPS cell derived secretome, where said iPS cells are derived from a mammal with a neurodegenerative pathology or a healthy mammal;
• c) a combination of soluble and exosome fractions of iPS cell derived secretome, where said iPS cells are derived from a mammal with a neurodegenerative pathology or a healthy mammal;
• d) proteins that are secreted by induced pluripotent stem cells (iPSCs) derived from a mammal with a neurodegenerative pathology or a healthy mammal where said proteins are secreted when said iPSC cells are pluripotent or biologically active fragments of said proteins and/or biologically active analogs of said proteins;
• and/or
• e) combinations of 2 or more proteins shown in Table 9, or biologically active fragments of said proteins and/or biologically active analogs of said proteins.